<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968016</url>
  </required_header>
  <id_info>
    <org_study_id>Troponin T</org_study_id>
    <nct_id>NCT03968016</nct_id>
  </id_info>
  <brief_title>Reference Interval Validation of High-Sensitivity Cardiac Troponin T Assay in Thai Population</brief_title>
  <official_title>Reference Interval Validation of High-Sensitivity Cardiac Troponin T Assay in Thai Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to study the cut-off of high sensitivity troponin T using SYSMEX
      HLSCL Machine in Thai population at percentile 99.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 27, 2019</start_date>
  <completion_date type="Actual">May 10, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of high sensitivity-troponin T level</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Diagnoses Disease</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable heart disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stable heart disease and non-hospitalized</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SYSMEX HLSCL</intervention_name>
    <description>Diagnostic device</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Stable heart disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For healthy group

        Inclusion Criteria:

          -  Group 1: Aged 18 - 40 years

          -  Group 2: Aged &gt; 40 - 70 years

          -  A presumably healthy population will define from a health questionnaire

        Exclusion Criteria:

          -  Heart diseases

          -  Renal diseases (CKD or recent AKI)

          -  History of pulmonary embolism

        For Patient group with stable heart diseases

        Inclusion Criteria:

          -  Aged &gt; 40 - 70 years

          -  Stable heart disease individuals will be evaluated by cardiologist

          -  Non hospitalized (OPD settings)

        Exclusion Criteria:

          -  Stable heart diseases with ACS

          -  Renal diseases (CKD or recent AKI)

          -  History of pulmonary embolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Pathum Wan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Cardiac marker</keyword>
  <keyword>Troponin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

